PHRM845-FINAL EXAM Flashcards

Pharmacotherapy of SUD

1
Q

What percentage of the population used an illicit substance in the past year?

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What was the highest used illicit substance in the past year?

A
  1. Marijuana
  2. Hallucinogens
  3. Rx pain reliever misuse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The first couple of times for using illicit substances is for ____

A

To feel good/get high

**then pts start to believe they need it to deal with life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2 biggest sources of pain relievers for misuse

A
  1. Prescription from doctor (~40%)
  2. Given by, bought from, or took from a friend or relative (~44.6%)

**We spend a lot of time focusing on pts that get meds from more than 1 doctor, but that only makes up 2.2%
**<10% of people are buying these meds off the street

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

____ is associated with substance use

A

Mental health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Psychiatrists silo mental health and substance use…only focus on ___ aspect

A

Mental health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

40.9% of adults get no tx for their SUD or MHD. What are some reasons for this?

A

-Access issue and number of providers issue
-Feel stigmatized and don’t want to engage
-Lots of steps/barriers to getting meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Indiana’s efforts to combat prescription drug misuse

A
  1. INSPECT program
  2. Indiana Medical Licensing Board Rules (certain pts have to agree to toxicology screening)
  3. Indiana Medicaid
  4. Improving access to naloxone
  5. Expanding SUD tx centers/methadone clinics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which population had the hardest access to substance use treatment?

A

Pregnant women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Examples of DSM-5, TR substances for substance use disorders

A
  1. Alcohol
  2. Caffeine
  3. Cannabis
  4. Hallucinogens
  5. Inhalants
  6. Opioids
  7. Sed/hyp/anxio
  8. Stimulants (Rx and OTC)
  9. Tobacco
  10. Other
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DSM-5, TR SUD indications

A

-Deleted the terms “abuse” and “dependence”
-These were considered to be indicators of severity of illness based on number of criteria met and timeframe of substance misuse
-The DSM-5 combine the criteria into SUD (criteria are applied to 10 different drug classes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SUD classification (Applies for all substances)

A

2 of the following must occur in a 12-month period
1. Taken in larger amounts or over a longer period than intended
2. Persistent desire or unsuccessful efforts to cut down or control use
3. Great deal of time spent in activities necessary to obtain substance or recover from use
4. Craving, strong desire, or urge to use
5. Recurrent use results in failure to fulfill major role obligations
6. Continued use despite consistent or recurrent social or interpersonal problems caused or exacerbated by use or effects of use
7. Important activities are given up or reduced
8. Recurrent use in situations in which it is physically dangerous (ex: drunk driving)
9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem related to use
10. Tolerance (needing increased amounts to achieve effect or diminished effect with continued use of the same amount)
11. Withdrawal (characteristic syndrome OR substance is used to relieve or avoid withdrawal symptoms)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical course of SUD

A

-Runs in families
-Hard to know if it is environmental or hereditary
-See in younger age (onset late teens/early 20’s) b/c brain is a risk-taker at that age
-Most young people will have a drug of choice eventually
-Younger users are more likely to experiment with different drugs; older users generally have a substance of choice, but don’t limit to that drug
-Chronic course with periods of partial or complete remission (best sustained with formal tx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Risk of setbacks
(previously referred to as relapse)

A

-Greatest during the first years of tx
-More likely in first 12 months of abstinence
-Majority will be able to maintain complete or partial remission
-90% of ppl abstinent at 2 years will be abstinent at 10 years
->90% abstinent at 10 years will be abstinent at 20 years
-It takes 2 years to reset the nucleus accumbens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tx principles

A

-The person with SUD is ALWAYS RECOVERING
-Long-term tx is necessary to reduce risk of setbacks
-No one is perfect
-Pt MUST be engaged in tx, significant work by both tx providers and pt to maintain abstinence
-Providers must not be judgmental
-Tx includes pharmacotherapy and psychotherapy (includes group and individual tx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Presentation of pt with BAC 50 mg/dl (0.05mg%)

A

Motor function impairment is observable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Presentation of pt with BAC 80 mg/dl (0.08mg%)

A

-Legal limit in most states
-Don’t realize rxn time is slower
-Moderate impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Presentation of pt with BAC 450 mg/dl

A

Respiratory depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Presentation of pt with BAC 500 mg/dl

A

Lethal dose for ethanol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Stage 1 of alcohol withdrawal
-Time of onset
-Clinical features

A

~6-8 hours
~Moderate autonomic hyperactivity (anxiety, tremors, tachycardia, insomnia, N/V, diaphoresis) and a craving for alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Stage 2 of alcohol withdrawal
-Time of onset
-Clinical features

A

~24 hours
~Autonomic hyperactivity with auditory/visual hallucinations lasting ~1-3 days (most remain lucid and oriented)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Stage 3 of alcohol withdrawal
-Time of onset
-Clinical features

A

~1-2 days
~4% if those untreated develop grand mal seizures about 7-48 hours after drop in BAC

23
Q

Stage 4 of alcohol withdrawal
-Time of onset
-Clinical features

A

~3-5 days (~96 hours=4d)
~Delirium tremens (DTs) in ~5% of pts=confusion, illusions, hallucinations, agitation, tachycardia, hyperthermia

24
Q

Mortality associated with DTs ~5-15% attributable to ___

A

Arrhythmias
Shock
Infection
Trauma
Aspiration

25
Q

Risk factors for DTs

A

-Prior hx of DTs
~#1 predictor
~Kindling: repeated withdrawal episodes increase the severity of subsequent withdrawal symptoms
-Number of detoxifications (in & out of detox center)
-Consuming the equivalent of 1 pint of whiskey per day for 10 of 14 days prior to admission
-Early symptoms of withdrawal
-Hepatic dysfunction

26
Q

Clinical institute withdrawal assessment to determine if a pt is experiencing alcohol withdrawal in the inpatient setting.

A

-Validated scale: used in clinical settings to assess withdrawal severity
-Ranks: N/V, tremors, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory & visual hallucinations, HA or fullness in head, orientation, clouding of sensorium
-Scored from 0-7 for each symptom type
-Med administration based on score

27
Q

Tx alcohol withdrawal

A

BENZODIAZEPINE
-If no liver dysfunction, use diazepam/chlordiazepoxide
~Long half-life
~May also use lorazepam and oxazepam
-If liver dysfunction, use lorazepam or oxazepam
~Non-active metabolites

28
Q

Other treatment considerations for alcohol withdrawal: thiamine!!!!

A

-ALWAYS recommend if any suspicion of alcohol use
-Dose: 100 mg PO QD, usually for duration of hospital stay, may be given after discharge; not considered long-term treatment

29
Q

Other treatment considerations for alcohol withdrawal: Carbamazepine

A

-May be effective for mild/moderate symptoms
-Unclear if it prevents seizures or DTs

30
Q

Other treatment considerations for alcohol withdrawal: Valproic acid

A

May reduce severity of alcohol withdrawal symptoms, including seizures

31
Q

Other treatment considerations for alcohol withdrawal: phenytoin

A

-Not effective to treat withdrawal seizures, but will see pts taking months or years out from withdrawal seizures-d/c????

***DOES NOT WORK FOR PEOPLE WITH SEIZURES

32
Q

What can happen if thiamine is not replaced in a patient?

A

They can develop wernicke-korsakoff syndrome
-Wernicke’s encephalopathy
~Result of thiamine deficiency
~Give before dextrose-containing fluid
~Thiamine is a co-factor in glucose metabolism, Wernicke’s can be precipitated by high glucose loads
~May require higher doses in first 24 hours
~Can switch to PO tx after first 24-48 hours IV

-Korsakoff’s psychosis
~Chronic condition
~Treat with antipsychotics
~If pt had Wernicke’s several times, they will eventually go to this

33
Q

Pharmacotherapy of AUD

A

-Can help to maintain abstinence, reduce craving, reduce drinking days, reduce quantity of alcohol consumed on drinking days
-Can be aversive therapy–“punishes” pt for consuming alcohol
-Most drug tx used in AUD do not cause significant adverse effects when combined with alcohol, rather they reduce cravings and binge drinking amounts
-Pharmacotherapy often provides the pt with knowledge that they are taking medication to help them reduce cravings, so there is a “placebo” effect in addition to drug effect
-Drug tx is not a “magic bullet”, psychotherapy is needed
-Pt must be integrated into care and make a commitment
-Combo tx with differing MOA may be used in clinical practice; studies to date do not show much greater efficacy
-Growing evidence for the use of gabapentin for the tx of AUD; limited evidence for topiramate and olanzapine

34
Q

Disulfiram (Antabuse)

A

-Aversive tx (blocks ALDH)
-Unpleasant effects if alcohol is used (flushing, N/V, tachycardia)
-Potential for cardiovascular collapse; death
-Must have highly motivated pt
-Monitor LFTs
-250 mg PO QD is usual maintenance dose
-Disulfiram rxn for up to 14 days after d/c MUST stop 2 weeks before contact with alcohol, or else pt will have a rxn
-Topical use of alcohol will cause nausea as well (perfume, hand sanitizer, etc.)

35
Q

Acamprosate (Campral)

A

-Wish it worked better
-Maintenance of abstinence
-Renal elimination, monitor renal function and avoid if pt has severe renal impairment
-Suicidality warning
-SE also include diarrhea, nausea, depression, and anxiety **No age range with this med; contact prescriber if feeling these sx
-Dose is 333 mg tablets–2t PO TID (total 666 mg)
-Is safe to take if the person uses alcohol
-Clinical effectiveness is limited by the number of tablets and doses per day

36
Q

Naltrexone

A

-Decreases craving of opioid and alcohol
-Clinical trials show best response to naltrexone over acamprosate in combo with psychotherapy
-Available in oral and IM doses
-Decreases binge drinking, helps to increase time between drinking days
-Elevated LFTs common; must monitor at baseline and routinely
-Need to evaluate pain management needs (Pt should have wallet card or be able to tell emergency providers that they are taking this)
-Oral dose is 50 mg PO QD (couple times to ensure pt tolerates it; PO is not preferred)
-IM dose is brand only and very expensive
-Warning for injection site rxns
(necrotic areas–>inflammation)

37
Q

Treating opioid withdrawal

A

-Very uncomfortable; worst type of flu feeling
-Short-term tapering doses of opioids or buprenorphine may be used in withdrawal period
-Buprenorphine should not be initiated until 12-18h after the last use of a short-acting opioid (heroin or oxycodone) and 24-48h after the last use of methadone

38
Q

How to tx sx of opioid withdrawal: muscle aches/tension

A

Acetaminophen or NSAID

39
Q

How to tx sx of opioid withdrawal: Agitation/anxiety/insomnia

A

Hydroxyzine
*Benzo if hydroxyzine does not work

40
Q

How to tx sx of opioid withdrawal:
Abdominal cramping/N/V

A

Ondansetron

41
Q

How to tx sx of opioid withdrawal: Diarrhea

A

Loperamide

42
Q

How to tx sx of opioid withdrawal:
Sweating/yawning/increased tearing/runny nose

A

Clonidine
*Lofexidine if clonidine does not work

43
Q

Use of alpha-2 agonists for opioid withdrawal symptoms

A

-Good for seeking behavior
-Noradrenergic hyperactivity causes many of the opioid withdrawal symptoms, leading to increased risk of setback
-Tx nonadrenergic sx can serve as an entry to longer-term tx with MOUD and psychosocial tx
-Craving is thought to be mediated by the mesolimbic reward pathway; physical withdrawal symptoms mediated by the locus coerulus (noradrenergic)

44
Q

Clonidine dosing

A

0.3-0.6 mg/day (mild withdrawal)
Up to 1.2 mg/day (severe withdrawal)
*Divided doses (0.1-0.2 mg/dose given up to hourly)
**Hypotension is the most common SE; less likely with lofexidine

45
Q

Lofexidine dosing

A

0.54 mg (3 tablets) QID x 5-7d
Max dose: 2.88 mg/day (16 tabs)
No single dose >0.72 mg (4 tabs)
May continue for up to 14d
Dosing adjustments in renal and hepatic impairment
**MUCH MORE EXPENSIVE

46
Q

American Society of Addiction Medicine (ASAM) guidelines

A

-Patients should be offered all forms of meds for opioid use disorder (MOUD) where possible and available
-Psychotherapy should be offered, but prescribing MOUD should not be contingent on the pt agreeing to psychotherapy or other types of therapy
-Pregnant women should be screened for OUD in prenatal care and offered either buprenorphine or methadone; limited data regarding use of naltrexone; if a pregnant women is taking naltrexone, provide education about risks/benefits (DO NOT USE NALTREXONE FOR PREGNANT PT)
-Incarcerated pts with OUD should be screened for OUD and offered tx in jail/prison setting; should NOT be required to switch meds if entering incarceration on medication; opioid withdrawal should be treated medically (MUST get pt access to the med they were on)
-Combo tx with opioids and benzos is NOT recommended due to increased risk of fatal OD

47
Q

Maintenance tx of OUD

A

-Methadone and buprenorphine are the oral drugs used for maintenance tx
-Methadone must be given in a licensed tx program every single day
-Buprenorphine is usually given in combo with naloxone in a SL tablet or film strip dosage form; poor bioavailability when swallowed so it must be SL **Naloxone has no benefit, but people were scared the straight opioid would be abused
-X-waivered prescriber is no longer needed to write a buprenorphine prescription

48
Q

Methadone tx pearls

A

-Long half life: once daily dosing is appropriate for use in methadone clinic or opioid tx programs (must come in every day to prevent unintentional OD)
-Witnessed dosing, pts must “earn” take-home bottles
-Urine tox screen should be positive for methadone, generally negative for everything else
-P450 2B6, 3A4, 2C19, and 2D6 substrate: use with caution in pts also taking moderate to strong inhibitors or inducers
-Due to long half-life, there is a concern for ADR several days after initiating dosing–titrate slowly to dose that minimizes withdrawal sx, but does not provide euphoric effect
-QTc prolongation is a serious concern-ECG monitoring is recommended

49
Q

Buprenorphine clinical pearls

A

-Need to decrease stigma around it
-Given with naloxone in the same dosage form to decrease misuse-naloxone is not absorbed through the GI tract, so no effect if taken SL; but if injected, will block opiate effect of buprenorphine
-To avoid precipitating withdrawal, initiate tx when there are clear signs of withdrawal; administer in divided doses on day 1
-Available in SL films & tablets; must be doses SL due to lack of gastric absorption
-3A4 substrate–monitor closely when used with 3A4 inhibitors or inducers
-Monitor LFTs; use with serotonergic drugs may causes serotonin syndrome (MUST MONITOR)
-Risk of respiratory depression in OD is much less than with opioids, including methadone, due to partial agonist effect

50
Q

Buprenorphine ER injection (Sublocade; Brixadi)

A

-Moderate-severe opioid use disorder; pts initiated on SL buprenorphine and dose adjustment for at least 7 days prior to first injection (to ensure tolerance)
-REMS
-3A4 substrate (monitor with 3A4 inhibitors and inducers)
-Monitor for use with serotonergic meds–risk for serotonin syndrome

51
Q

Should we choose methadone or buprenorphine?
**Must consider SDOH

A

Methadone
-more effective; gives pt accountability
-Can take home liquid form in bottles (2 weeks worth) if adherent for at least 1 year.
-Clinical proof of efficacy
-FDA approved for use in pregnancy
-Tx program requires daily attendance unless pt graduates to take-home bottles
-Must give urine samples and attend programming
-Indiana Medicaid covers under medical billing
-Stigma of program
-Transportation?

Buprenorphine
-Effective tx over short-term, longer-term clinical trials lacking
-Office-based; can get 30d Rx
-Less stigma
-Less misuse potential over methadone
-Indiana Medicaid covers
-Removal of X-waiver prescribing requirement may increase access

52
Q

Naltrexone long-acting injection (Vivitrol)

A

-FDA approved to tx OUD
-Given in same dose as AUD (good for pts who have OUD and AUD)
-Concern in OUD for pts trying to “overcome” opioid receptor blockade with higher opioid doses
-Must let pt know about pain management issues—need to let provider know if injured or in need of acute pain management
-Is the “abstinence” tx, patients MUST be ready for this, discuss with pt about readiness to encourage adherence with ongoing dosing (Don’t get ANY effect from taking opioid; challenging if pt feels they need opioid to “get through the day”
-Risk of OD if pt d/c tx; must tell pt of this risk
***Do not have tolerance anymore so we cannot use dose they were using previously

53
Q

Naloxone kits

A

-Aaron’s law removes civil liability for dispensing of naloxone except for negligence or willful misconduct
-Pharmacies are now allowed to dispense naloxone kits w/o a script under a standing order between a prescriber and a pharmacy/pharmacist.
-Prescriber does not have to have a relationship with the pt
-2 doses of naloxone per dispensing to allow for enough doses for EMTs to arrive
-Indiana Medicaid covers naloxone kits in a limited number/year
-March 30, 2023–FDA approved OTC naloxone nasal spray (Narcan, 4 mg)

54
Q

Tx for other substances

A

-There are no drug tx FDA-approved to tx addiction to other illicit substances–cocaine, amphetamines, bath salts, K2, marijuana
-Supportive care is used in the emergency setting for each of these drugs based on pt presentation
-Psychosis that results from either K2/Spice or bath salts intoxication is not generally responsive to tx with antipsychotics
-Deaths have resulted from use of K2/spice or bath salts due to cardiovascular collapse, hypokalemia, and seizures
-Use of beta-blockers to tx HTN in cocaine intoxication is controversial–long believed to cause cardiovascular collapse
-Depression due to substance withdrawal is common–may last for months after d/c use of cocaine–treat like clinical depression (Use PHQ-9); depends on how long substance has been gone and pts mood